XML 53 R24.htm IDEA: XBRL DOCUMENT

Acquisitions, Investments, and Licenses (Tables)

6 Months Ended

Jun. 30, 2015

Maximum exposure of unconsolidated investments

The following table reflects the accounting method, carrying value and underlying equity in net assets of our unconsolidated investments as of June 30, 2015:



(in thousands)
Investment type	Investment Carrying Value		Underlying Equity in Net Assets
Equity method investments	$	6,746	$	23,735
Variable interest entity, equity method	903		—
Available for sale investments	3,816
Warrants and options	9,969
Total carrying value of investments	$	21,434

EirGen Pharma Ltd

Business Acquisition [Line Items]

Schedule of Purchase Price Allocation

The following table summarizes the preliminary purchase price allocation and the estimated fair value of the net assets acquired and liabilities assumed in the acquisition of EirGen at the date of acquisition. The purchase price allocation for EirGen is preliminary:



(In thousands)	EirGen
Current assets ⁽¹⁾	$	11,795
Intangible assets:
IPR&D assets	19,597
Customer relationships	34,155
Currently marketed products	3,919
Total intangible assets	57,671
Goodwill	66,823
Property, plant and equipment	8,117
Other assets	1,232
Accounts payable and other liabilities	(6,254		)
Deferred tax liability	(5,618		)
Total purchase price	$	133,766

(1)Current assets include cash, accounts receivable, inventory and other assets of $5.5 million, $2.7 million, $2.2 million and $1.4 million, respectively, related to the EirGen acquisition. The fair value of the accounts receivable equals the gross contractual amount at the date of acquisition.

Schedule of Pro Forma

The following table includes the pro forma results for the three and six months ended June 30, 2015 and 2014 of the combined companies as though the acquisition of EirGen had been completed as of the beginning of the period presented.



	For the three months ended June 30,		For the six months ended June 30,
(In thousands)	2015	2014	2015	2014
Revenues	$43,848	$25,659	$76,769	$50,185
Net loss	(43,420)	(28,356)	(162,331)	(75,879)
Net loss attributable to common shareholders	(42,945)	(27,759)	(160,931)	(74,742)
Basic and diluted net loss per share	$(0.09)	$(0.07)	$(0.35)	$(0.18)

SciVac

Business Acquisition [Line Items]

Summary of consolidated assets and non-recourse liabilities related to SciVac

The following table represents the consolidated assets and non-recourse liabilities related to SciVac as of June 30, 2015 and December 31, 2014. These assets are owned by, and these liabilities are obligations of, SciVac, not us.



(In thousands)	June 30, 2015		December 31, 2014
Assets
Current assets:
Cash and cash equivalents	$	21	$	393
Accounts receivable, net	304		316
Inventories, net	1,433		1,649
Prepaid expenses and other current assets	774		718
Total current assets	2,532		3,076
Property, plant and equipment, net	1,791		1,725
Intangible assets, net	843		875
Goodwill	1,602		1,553
Other assets	368		384
Total assets	$	7,136	$	7,613
Liabilities
Current liabilities:
Accounts payable	$	900	$	445
Accrued expenses	4,476		4,446
Notes payable	5,409		5,189
Total current liabilities	10,785		10,080
Other long-term liabilities	1,884		2,042
Total liabilities	$	12,669	$	12,122

- Definition

Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.

+ References + Details